Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 6:2019:5870239.
doi: 10.1155/2019/5870239. eCollection 2019.

Assessment of the SFlt-1 and sFlt-1/25(OH)D Ratio as a Diagnostic Tool in Gestational Hypertension (GH), Preeclampsia (PE), and Gestational Diabetes Mellitus (GDM)

Malgorzata Walentowicz-Sadlecka  1 , Piotr Domaracki  1 , Pawel Sadlecki  1 , Joanna Siodmiak  2 , Marek Grabiec  1 , Pawel Walentowicz  1 , Maria Teresa Arias Moliz  3 , Grazyna Odrowaz-Sypniewska  1
Affiliations

Assessment of the SFlt-1 and sFlt-1/25(OH)D Ratio as a Diagnostic Tool in Gestational Hypertension (GH), Preeclampsia (PE), and Gestational Diabetes Mellitus (GDM)

Malgorzata Walentowicz-Sadlecka et al. Dis Markers. .

Abstract

Background: Placental soluble fms-like tyrosine kinase-1 (sFlt-1), an antagonist of vascular endothelial growth factor, is considered an etiological factor of endothelial damage in pregnancy pathologies. An increase in the sFlt-1 level is associated with alterations of endothelial integrity. In contrast, vitamin D exerts a protective effect and low concentrations of 25(OH)D may have an adverse effect on common complications of pregnancy, such as gestational hypertension (GH), preeclampsia (PE), and gestational diabetes mellitus (GDM). The aim of this study was to analyze the levels of sFlt-1 in Polish women with physiological pregnancies and pregnancies complicated by GH, PE, and GDM. Moreover, we analyzed relationships between the maternal serum sFlt-1 level and the sFlt-1 to 25(OH)D ratio and the risk of GH and PE.

Material and methods: The study included 171 women with complicated pregnancies; among them are 45 with GH, 23 with PE, and 103 with GDM. The control group was comprised of 36 women with physiological pregnancies. Concentrations of sFl-1 and 25(OH)D were measured before delivery, with commercially available immunoassays.

Results: Women with GH differed significantly from the controls in terms of their serum sFlt-1 levels (5797 pg/ml vs. 3531 pg/ml, p = 0.0014). Moreover, a significant difference in sFlt-1 concentrations was found between women with PE and those with physiological pregnancies (6074 pg/ml vs. 3531 pg/ml, p < 0.0001). GDM did not exert a statistically significant effect on serum sFlt-1 levels. Both logistic regression and ROC analysis demonstrated that elevated concentration of sFlt-1 was associated with greater risk of GH (AUC = 0.70, p = 0.0001) and PE (AUC = 0.82, p < 0.0001). Also, the sFlt-1 to 25(OH)D ratio, with the cutoff values of 652 (AUC = 0.74, p < 0.0001) and 653 (AUC = 0.88, p < 0.0001), respectively, was identified as a significant predictor of GH and PE.

Conclusions: Determination of the sFlt-1/25(OH)D ratio might provide additional important information and, thus, be helpful in the identification of patients with PE and GH, facilitating their qualification for intensive treatment and improving the neonatal outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
ROC curve—relationship between sFlt-1 concentrations (pg/ml) and occurrence of gestational hypertension (AUC 70.1%).
Figure 2
Figure 2
ROC curve—relationship between sFlt-1 concentrations (pg/ml) and occurrence of preeclampsia (AUC 82.4%).
Figure 3
Figure 3
ROC curve—relationship between sFlt-1/25(OH)D index and occurrence of gestational hypertension (AUC 73.6%).
Figure 4
Figure 4
ROC curve—relationship between sFlt-1/25(OH)D index and occurrence of preeclampsia (AUC 87.96%).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Buchanan T. A., Xiang A. H., Page K. A. Gestational diabetes mellitus: risks and management during and after pregnancy. Nature Reviews Endocrinology. 2012;8(11):639–649. doi: 10.1038/nrendo.2012.96. - DOI - PMC - PubMed
    1. Su C. Y., Lin H. C., Cheng H. C., Yen A. M. F., Chen Y. H., Kao S. Pregnancy outcomes of anti-hypertensives for women with chronic hypertension: a population-based study. PLoS One. 2013;8(2, article e53844) doi: 10.1371/journal.pone.0053844. - DOI - PMC - PubMed
    1. Gillon T. E. R., Pels A., von Dadelszen P., MacDonell K., Magee L. A. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One. 2014;9(12, article e113715) doi: 10.1371/journal.pone.0113715. - DOI - PMC - PubMed
    1. Nilsen R. M., Vik E. S., Rasmussen S. A., et al. Preeclampsia by maternal reasons for immigration: a population-based study. BMC Pregnancy and Childbirth. 2018;18(1):p. 423. doi: 10.1186/s12884-018-2034-4. - DOI - PMC - PubMed
    1. Plows J. F., Stanley J. L., Baker P. N., Reynolds C. M., Vickers M. H. The pathophysiology of gestational diabetes mellitus. International Journal of Molecular Sciences. 2018;19(11, article 3342) doi: 10.3390/ijms19113342. - DOI - PMC - PubMed

Substances